Predicting the Risk of Relapse with IMMUNOSCORE®: Evaluating Rectal cancer prognosis

By providing an accurate measurement of T lymphocyte infiltration into the tumor, Immunoscore® gives healthcare providers insight into the risk of relapse.
A low or intermediate Immunoscore® means there are few T-cells present to fight the cancer, indicating a high risk of relapse. Conversely, a high Immunoscore® means there is high infiltration of T lymphocytes, indicating a lower risk of relapse.



Benefits in the Clinic
Helping physicians identify candidates for Nonoperative Management (Watch and Wait) with Immunoscore® for Rectal Cancer
Management of patients with LARC is changing[1,2]. Patients who show a clinically complete response (cCR) to neoadjuvant treatment (NT) may be able to avoid total mesorectal excision (TME), a procedure which can lead to low patient quality of life[3].
But identifying the right patients for Nonoperative Management (Watch and Wait) has been difficult in the absence of a reliable biomarker predicting the risk of cancer recurrence.
A new study[4] has shown that Immunoscore® combined with imaging was able to identify very good responders to NT that could benefit from organ preservation strategy. In the "Watch and Wait" cohort, 100% success was observed in patients with Immunoscore High.
IMMUNOSCORE® predicts the clinical outcome of LARC patients[4]
Patients with Immunoscore High have a good clinical outcome (5 yr disease-free survival: 89% vs 63% vs 55%).


LARC patients treated with CRT and radical surgery (n=238).


LARC patients with complete clinical response to chemoradiotherapy
(n=73).
Immunoscore® selects LARC patients eligible for “Watch and Wait” approach[4]
Patients with complete clinical response and Immunoscore High do not relapse and may be eligible for organ preservation.
5 yr disease-free survival of patients treated with CRT and radical surgery by Immunoscore[4] :
89%
with Immunoscore High
63%
with Immunoscore Intermediate
55%
with Immunoscore Low
Frequently Asked Questions
Immunoscore® is a tissue-based immune test that measures the host's immune response at the site of the tumor. It is performed on formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from resections of Locally Advanced Rectal Cancer (LARC). The test uses whole slide imaging and artificial intelligence algorithms for assessment of the type, density, and location of T cells in FFPE tumor sections to determine an individual Immunoscore® for each patient.
In combination with TNM classification and other relevant clinical and biological data, IMMUNOSCORE® guides physicians on whether to propose a Nonoperative Management (Watch and Wait) approach to patients with a complete clinical response after neo-adjuvant treatment.
Once a sample is received by our laboratory, it should take no more than 10 working days to provide you with the result.
Interested in ordering A test?
Select your Country
Immunoscore® for the management of locally advanced rectal cancer (LARC) is available in select locations through an Innovation Access Program (IAP). Find out if you can participate in the IAP by filling in the contact form below.
Contact us for details as the test is not available in the US


Veracyte SAS
Luminy Biotech Entreprises
163 Avenue de Luminy
13288 Marseille Cedex 9
FRANCE
Phone No : +33 (0) 4 91 29 30 90
Contact Form
You provided us with email information that we will use to contact you about our products and services. The information will not be sold to any third party. Veracyte may transfer your personal information to our CRM systems solely for the purposes of data hosting, marketing actions and to our distributor partners for commercial activity.
You may unsubscribe at any time by sending an email at privacy@haliodx.com. For information on our privacy practices and commitment to protecting your privacy, please review our Privacy policy.
our programs
Immunoscore® for Rectal Cancer is available Out of US through our Access Program. Please contact us to know more by filling in the contact form above.
Top Resources for healthcare professionals
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment


Brochure Immunoscore in Rectal Cancer
Contact Our Team to Inquire About IMMUNOSCORE
Distributor and commercial team area
References
- Hill GL and Rafique M. Extrafascial excision of the rectum for rectal cancer. Br J Surg. 1998 Jun;85(6):809-12.
- Bjerkeset T and Edna TH. Rectal cancer: the influence of type of operation on local recurrence and survival. Eur J Surg. 1996 Aug;162(8):643-8.
- Pieniowski EHA, et al. Prevalence of low anterior resection syndrome and impact on quality of life after rectal cancer surgery: population-based study. BJS Open. 2020 Oct;4(5):935-942.
- El Sissy C, et al. A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. Clin Cancer Res. 2020 Oct 1;26(19):5198-5207.
- Anitei M-G, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014 Apr 1;20(7):1891-9.